A molecular approach for diagnosing prostate cancer
麻豆原创 Analysis and Insights: Global Prostate Cancer Molecular Diagnostics 麻豆原创
The global Prostate Cancer Molecular Diagnostics market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Prostate Cancer Molecular Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for Prostate Cancer Molecular Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for Prostate Cancer Molecular Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key companies of Prostate Cancer Molecular Diagnostics include Qiagen, Foundationmedicine, Genetech, Gpmedical, Premed, Berryoncology, Gene+, Annoroad and Topgen, etc. in 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Prostate Cancer Molecular Diagnostics market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Prostate Cancer Molecular Diagnostics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Prostate Cancer Molecular Diagnostics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Prostate Cancer Molecular Diagnostics revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Prostate Cancer Molecular Diagnostics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Prostate Cancer Molecular Diagnostics revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Qiagen, Foundationmedicine, Genetech, Gpmedical, Premed, Berryoncology, Gene+, Annoroad and Topgen, etc.
By Company
Qiagen
Foundationmedicine
Genetech
Gpmedical
Premed
Berryoncology
Gene+
Annoroad
Topgen
Geneis
Segment by Type
PCR
FISH
DNA Sequencing
Gene Chip
Segment by Application
Clinical Diagnosis
Drug Screening
Research
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Prostate Cancer Molecular Diagnostics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Prostate Cancer Molecular Diagnostics companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Prostate Cancer Molecular Diagnostics revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Prostate Cancer Molecular Diagnostics 麻豆原创 Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 PCR
1.2.3 FISH
1.2.4 DNA Sequencing
1.2.5 Gene Chip
1.3 麻豆原创 by Application
1.3.1 Global Prostate Cancer Molecular Diagnostics 麻豆原创 Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Clinical Diagnosis
1.3.3 Drug Screening
1.3.4 Research
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Prostate Cancer Molecular Diagnostics 麻豆原创 Perspective (2018-2029)
2.2 Global Prostate Cancer Molecular Diagnostics Growth Trends by Region
2.2.1 Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Prostate Cancer Molecular Diagnostics Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Prostate Cancer Molecular Diagnostics Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Prostate Cancer Molecular Diagnostics 麻豆原创 Dynamics
2.3.1 Prostate Cancer Molecular Diagnostics Industry Trends
2.3.2 Prostate Cancer Molecular Diagnostics 麻豆原创 Drivers
2.3.3 Prostate Cancer Molecular Diagnostics 麻豆原创 Challenges
2.3.4 Prostate Cancer Molecular Diagnostics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Prostate Cancer Molecular Diagnostics by Players
3.1.1 Global Prostate Cancer Molecular Diagnostics Revenue by Players (2018-2023)
3.1.2 Global Prostate Cancer Molecular Diagnostics Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Prostate Cancer Molecular Diagnostics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Prostate Cancer Molecular Diagnostics, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Prostate Cancer Molecular Diagnostics 麻豆原创 Concentration Ratio
3.4.1 Global Prostate Cancer Molecular Diagnostics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Prostate Cancer Molecular Diagnostics Revenue in 2022
3.5 Global Key Players of Prostate Cancer Molecular Diagnostics Head office and Area Served
3.6 Global Key Players of Prostate Cancer Molecular Diagnostics, Product and Application
3.7 Global Key Players of Prostate Cancer Molecular Diagnostics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Prostate Cancer Molecular Diagnostics Breakdown Data by Type
4.1 Global Prostate Cancer Molecular Diagnostics Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Prostate Cancer Molecular Diagnostics Forecasted 麻豆原创 Size by Type (2024-2029)
5 Prostate Cancer Molecular Diagnostics Breakdown Data by Application
5.1 Global Prostate Cancer Molecular Diagnostics Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Prostate Cancer Molecular Diagnostics Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Prostate Cancer Molecular Diagnostics 麻豆原创 Size (2018-2029)
6.2 North America Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Type
6.2.1 North America Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Type (2018-2023)
6.2.2 North America Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Type (2024-2029)
6.2.3 North America Prostate Cancer Molecular Diagnostics 麻豆原创 Share by Type (2018-2029)
6.3 North America Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Application
6.3.1 North America Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Application (2018-2023)
6.3.2 North America Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Application (2024-2029)
6.3.3 North America Prostate Cancer Molecular Diagnostics 麻豆原创 Share by Application (2018-2029)
6.4 North America Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Country
6.4.1 North America Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Country (2018-2023)
6.4.3 North America Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Prostate Cancer Molecular Diagnostics 麻豆原创 Size (2018-2029)
7.2 Europe Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Type
7.2.1 Europe Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Type (2018-2023)
7.2.2 Europe Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Type (2024-2029)
7.2.3 Europe Prostate Cancer Molecular Diagnostics 麻豆原创 Share by Type (2018-2029)
7.3 Europe Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Application
7.3.1 Europe Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Application (2018-2023)
7.3.2 Europe Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Application (2024-2029)
7.3.3 Europe Prostate Cancer Molecular Diagnostics 麻豆原创 Share by Application (2018-2029)
7.4 Europe Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Country
7.4.1 Europe Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Country (2018-2023)
7.4.3 Europe Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Prostate Cancer Molecular Diagnostics 麻豆原创 Size (2018-2029)
8.2 China Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Type
8.2.1 China Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Type (2018-2023)
8.2.2 China Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Type (2024-2029)
8.2.3 China Prostate Cancer Molecular Diagnostics 麻豆原创 Share by Type (2018-2029)
8.3 China Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Application
8.3.1 China Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Application (2018-2023)
8.3.2 China Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Application (2024-2029)
8.3.3 China Prostate Cancer Molecular Diagnostics 麻豆原创 Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Prostate Cancer Molecular Diagnostics 麻豆原创 Size (2018-2029)
9.2 Asia Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Type
9.2.1 Asia Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Type (2018-2023)
9.2.2 Asia Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Type (2024-2029)
9.2.3 Asia Prostate Cancer Molecular Diagnostics 麻豆原创 Share by Type (2018-2029)
9.3 Asia Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Application
9.3.1 Asia Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Application (2018-2023)
9.3.2 Asia Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Application (2024-2029)
9.3.3 Asia Prostate Cancer Molecular Diagnostics 麻豆原创 Share by Application (2018-2029)
9.4 Asia Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Region
9.4.1 Asia Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Region (2018-2023)
9.4.3 Asia Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Prostate Cancer Molecular Diagnostics 麻豆原创 Size (2018-2029)
10.2 Middle East, Africa, and Latin America Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Prostate Cancer Molecular Diagnostics 麻豆原创 Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Prostate Cancer Molecular Diagnostics 麻豆原创 Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Prostate Cancer Molecular Diagnostics 麻豆原创 Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Qiagen
11.1.1 Qiagen Company Details
11.1.2 Qiagen Business Overview
11.1.3 Qiagen Prostate Cancer Molecular Diagnostics Introduction
11.1.4 Qiagen Revenue in Prostate Cancer Molecular Diagnostics Business (2018-2023)
11.1.5 Qiagen Recent Developments
11.2 Foundationmedicine
11.2.1 Foundationmedicine Company Details
11.2.2 Foundationmedicine Business Overview
11.2.3 Foundationmedicine Prostate Cancer Molecular Diagnostics Introduction
11.2.4 Foundationmedicine Revenue in Prostate Cancer Molecular Diagnostics Business (2018-2023)
11.2.5 Foundationmedicine Recent Developments
11.3 Genetech
11.3.1 Genetech Company Details
11.3.2 Genetech Business Overview
11.3.3 Genetech Prostate Cancer Molecular Diagnostics Introduction
11.3.4 Genetech Revenue in Prostate Cancer Molecular Diagnostics Business (2018-2023)
11.3.5 Genetech Recent Developments
11.4 Gpmedical
11.4.1 Gpmedical Company Details
11.4.2 Gpmedical Business Overview
11.4.3 Gpmedical Prostate Cancer Molecular Diagnostics Introduction
11.4.4 Gpmedical Revenue in Prostate Cancer Molecular Diagnostics Business (2018-2023)
11.4.5 Gpmedical Recent Developments
11.5 Premed
11.5.1 Premed Company Details
11.5.2 Premed Business Overview
11.5.3 Premed Prostate Cancer Molecular Diagnostics Introduction
11.5.4 Premed Revenue in Prostate Cancer Molecular Diagnostics Business (2018-2023)
11.5.5 Premed Recent Developments
11.6 Berryoncology
11.6.1 Berryoncology Company Details
11.6.2 Berryoncology Business Overview
11.6.3 Berryoncology Prostate Cancer Molecular Diagnostics Introduction
11.6.4 Berryoncology Revenue in Prostate Cancer Molecular Diagnostics Business (2018-2023)
11.6.5 Berryoncology Recent Developments
11.7 Gene+
11.7.1 Gene+ Company Details
11.7.2 Gene+ Business Overview
11.7.3 Gene+ Prostate Cancer Molecular Diagnostics Introduction
11.7.4 Gene+ Revenue in Prostate Cancer Molecular Diagnostics Business (2018-2023)
11.7.5 Gene+ Recent Developments
11.8 Annoroad
11.8.1 Annoroad Company Details
11.8.2 Annoroad Business Overview
11.8.3 Annoroad Prostate Cancer Molecular Diagnostics Introduction
11.8.4 Annoroad Revenue in Prostate Cancer Molecular Diagnostics Business (2018-2023)
11.8.5 Annoroad Recent Developments
11.9 Topgen
11.9.1 Topgen Company Details
11.9.2 Topgen Business Overview
11.9.3 Topgen Prostate Cancer Molecular Diagnostics Introduction
11.9.4 Topgen Revenue in Prostate Cancer Molecular Diagnostics Business (2018-2023)
11.9.5 Topgen Recent Developments
11.10 Geneis
11.10.1 Geneis Company Details
11.10.2 Geneis Business Overview
11.10.3 Geneis Prostate Cancer Molecular Diagnostics Introduction
11.10.4 Geneis Revenue in Prostate Cancer Molecular Diagnostics Business (2018-2023)
11.10.5 Geneis Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Qiagen
Foundationmedicine
Genetech
Gpmedical
Premed
Berryoncology
Gene+
Annoroad
Topgen
Geneis
听
听
*If Applicable.
